Laiqiang Huang

Professor of Life and Health Science & Technology, Tsinghua University (since 2003).

Pengcheng Scholar Distinguished Chair Professor

National-Level Science & Technology Leader, Overseas High-Level Talent, Shenzhen

Director, The Center for Biotechnology & BioMedicine

The Shenzhen Key Laboratory of Gene & Antibody Therapy, and

The State Key Laboratory of Health Science & Technology (in prep)

Vice Chairman (for Res and Collab), Division of Life & Health Sciences

Graduate School at Shenzhen, Tsinghua University

Prof. Laiqiang Huang joined Tsinghua University in 2003 as Professor and the Academic Leader of Division of Life Sciences, Graduate School at Shenzhen, Tsinghua University following more than 20 years of advanced education & training and conducting and directing research & development in top universities and biotech & biomed industry in the United States. As a recipient of the prestigious China National Scholarships for Graduate Studies in the U.S., he went to the States in 1982, and obtained his Ph.D. (1989) from University of California and Post-Doctorates from Stanford University. Prof. Huang subsequently worked at Stanford University Medical School and biotech companies in the Silicon Valley as top-level research scientists. At Tsinghua University Graduate School at Shenzhen, Prof. Huang directs the Center for Biotech & BioMedicine and the Shenzhen Key Lab of Gene & Antibody Therapy as well as the State Key Laboratory of Health Science & Technology (in prep), whose research program is centered on molecular & cellular biology andtherapeutics of cancer and other major diseases by integrating the following research areas and technological platforms:

1. Molecular & Cell Biology: Mechanisms of cancer and other major diseases;

2. Biotech & Biomedicine: Gene therapies, Antibody and peptides, Normal and cancer stem cells;

3. Nanomedicine Cross-Integrated with Biomedicine: Nano-based drug delivery & targeting, Nano/Bio therapeutics & diagnostics, Therapeutics from natural and other sources;

4. Genomics, evolutionary and plant biology with orchids as model organisms.

Prof. Huang has more than 100 publications from research work, many of which report breakthroughs or important advances in leading scientific journals including Nature,PNAS, Nature Genetics, J Biol Chem, Sci Rep, Mol Biol Cell, J Cell Sci, Int J Biochem Cell Biol, PLoS ONE, Apoptosis, Cell Cycle, Int J Oncol, J Neuro-Oncol, Cancer Gene Ther,Cancer Immunol Immunother,Integr Biol, Theranostics, Nanomed, Biomaterials, Adv Drug Deliv Rev, J Biomed Nanotechnol and Plant Physiol; and holds or has filed over a dozen of patents. Prof. Huang published the first Nature paper in the history of Shenzhen, which has been highly regarded in the world. Itwasfeatured and highlighted in Nature’s press release, contents cover and video online, and received worldwide coverage by both mainstream media and scientific and educational publications. Several other papers published in top journals by Prof. Huang have also been considered highly by the scientific world and received great interest and attention around the globe.

Since joining Tsinghua, Prof. Huang has received a series of domestic and international awards and honors including the Important Advances of Sciences in China, Breakthroughs in Life Sciences in Encyclopaedia Britannica Year in Review, All China Universities’ Top 10 Sci-Tech Achievements Finalist (11th), Tsinghua University Centennial Selection of Outstanding Sci-Tech Achievements, the First Class Sci-Tech Innovation Award of Shenzhen (twice), Natural Science Award of Shenzhen, Tsinghua University Outstanding Faculty Award, Pengcheng Scholar Distinguished Chair Professorship, National-Level Science & Technology Leader and Overseas High-Level Talent in Shenzhen, and Ding Ying Distinguished Chair Professorship. Prof. Huang has been invited to be keynote or plenary speaker at Nature Symposiums, World Congress of Vaccine, International Conference on Genomics, Centennial Lecture at SCAU, Tenth anniversary of Tsinghua Shenzhen, etc.; and has hosted distinguished speakers, including father of stem cell Prof. Irv Weissman from Stanford, renowned bio- and nano-meidical scientists Prof. Mark Kay from Stanford, Prof. Gerard Marriott from UC Berkeley, and Prof. Dennis Carson from UCSD, at prestigious forums such as the Tsinghua Forum, Tsinghua Global Vision Lectures, Zijing Forum, and Innovation Forum of Shenzhen. Prof. Huang is a member of or holds key posts in a number of academic professional organizations.

EDUCATION

Post Doctorate (1997), Stanford University School of Medicine, USA

Post Doctorate (1994), Stanford University Department of Biological Sciences and

Carnegie Institution of Washington, USA

Ph.D. (1989) and M.S. (1984), University of California, Davis, USA

RESEARCH AREAS

Molecular & cellular Biology andtherapeutics of cancer and other major diseases by integrating the following research areas and technological platforms:

1. Molecular & Cell Biology: Mechanisms of cancer and other major diseases;

2. Biotechnology & Biomedicine:

Gene therapies (including RNA and vaccines),

Antibody and peptide technologies and therapeutics,

Normal and cancer stem cells and therapeutics;

3. Nanomedicine Cross-Integrated with Biomedicine:

Nano-based drug delivery & targeting,

Nano/Bio therapeutics & diagnostics,

Therapeutics from natural and other sources;

4. Genomics, evolutionary and plant biology with orchids as model organisms.

ACADEMIC & PROFESSIONAL APPOINTMENTS

• 2012-present: Overseas High-Level Talent in Shenzhen (Certified)

• 2011-present: Director, The State Key Laboratory of Health Science & Technology (in-prep)

Graduate School at Shenzhen, Tsinghua University, China

• 2010-present: Vice Chairman for Research and Collaboration, Division of Life & HealthSciences, Graduate School at Shenzhen, Tsinghua University, China

• 2010-present: Co-Head, The Research Team for Innovative Drug Discovery

Graduate School at Shenzhen, Tsinghua University, China

• 2009-present: Pengcheng Scholar Distinguished Chair Professor,

Graduate School at Shenzhen, Tsinghua University, China

• 2009-present: National-Level Science & Technology Leader of Shenzhen (Certified)

• 2009-present: Ding Ying Distinguished Chair Professor, SCAU, China

• 2007-present: Member of the School Academic Council;

Graduate School at Shenzhen, Tsinghua University, China

• 2007-present: Director, The Shenzhen Key Laboratory of Gene & Antibody Therapy;

Graduate School at Shenzhen, Tsinghua University, China

• 2005-present: Director, The Center for Biotechnology & BioMedicine,

Graduate School at Shenzhen, Tsinghua University, China

• 2003-present: Professor, School of Life Sciences, Tsinghua University, Beijing, China;

Leading Professor, Division of Life & Health Sciences, and

Founding Head, Center for Biotechnology & BioMedicine,

Graduate School at Shenzhen, Tsinghua University, China

• 1999-2003: Senior Research Scientist (III, the top level), BD Clontech, and

Chief Scientist, Gencelmedix, Silicon Valley, USA

• 1997-1999: Research Scientist, Stanford University School of Medicine, USA

• 1994-1997: Postdoctoral Scholar, Laboratory of Experimental Oncology and

Department of Pathology, Stanford University School of Medicine, USA

• 1989-1994: Postdoctoral Scholar, Stanford University Department of Biological Sciences and

Carnegie Postdoctoral Fellow, Carnegie Institution of Washington, USA

• 1985-1986: Teaching Assistant, University of California, Davis, USA

• 1984-1989: Research Assistant, University of California, Davis, USA

• 1981-1985: National Scholar for Graduate Studies in the USA,

The Ministry of Education of China. (Arrived in USA 1982)

AWARDS & HONORS

• 2014 Shenzhen Natural Science Award, Shenzhen, China (2015)

• Tsinghua Centennial Selection of Outstanding Sci-Tech Achievements in the Past Century (2011)

• Tsinghua Shenzhen Graduate School Top 10 Sci-Tech Achievements in the Past Ten Years (2011)

• Top 100 Articles in the Last 30 YearsAward, Acta Ecologica Sinica (2011)

• 2008 Shenzhen Sci-Tech Innovation Award, Shenzhen, China (2009)

• 2006 Shenzhen Sci-Tech Innovation Award, Shenzhen, China (2007)

• Named as a Breakthrough by Encyclopaedia Britannica Year in Review2006, Life Sciences (2007)

• Entered in Encyclopaedia Britannica Book of the Year 2007 (2007)

• Elected as one of the Important Advances in Sciences in China in 2006 (2007)

• Nominee & Finalist (11th) for 2006 All China Universities’ Top 10 Sci-Tech Achievements (2006)

• Overseas High-Level Talent in Shenzhen – Peacock Plan (2012-)

• Renowned Scholar & Expert, the University Town of Shenzhen (2011-)

• Listed in Marquis Who’s Who in the World (2010)

• Ding Ying Distinguished Chair Professorship, SCAU (2009-)

• National-Level Science & Technology Leader of Shenzhen (2009-)

• Pengcheng Scholar Distinguished Chair Professorship, Tsinghua-Shenzhen (2009-)

• Outstanding University Faculty Award, Tsinghua University, China (2007)

• Outstanding School Faculty Award, Tsinghua University Graduate School at Shenzhen (2007)

• 2005 Important Research Project Award, Tsinghua University Graduate School at Shenzhen (2006)

• Peer-to-Peer Award (for solving critical technical problems), BD Clontech, USA, 2000

• School of Medicine Fellow, Stanford University School of Medicine, USA, 1994-97

• Carnegie PostDoctoral Fellowship, Carnegie Institution of Washington, Stanford, USA, 1989-92

• Jastro-Shields Outstanding Graduate Research Award, U. of California, Davis, USA, 1987-89

• Graduate Travel Awards, Shell Travel Awards, University of California, Davis, USA, 1987, 88, 89

• Teaching Assistantship Award, University of California, Davis, USA, 1985-86

• Research Assistantship Award, University of California, Davis, USA, 1984-89

• Non-Resident Tuition Awards, University of California, Davis, USA, 1984-86

• National Scholarship for Graduate Studies in U.S.A., The Ministry of Education of China, 1981-85

PUBLICATIONS

(Huang Laiqiang or Huang Lai-Qiang or Huang LQ and Tsinghua; and Huang Lab at Tsinghua)

JOURNALS (in recent five years)

[1] Jing Cai#, Xin Liu, Kevin Vanneste, Sebastian Proost, Wen-Chieh Tsai, Ke-Wei Liu#, …… Lai-Qiang Huang*, Yi-Bo Luo, Hong-Hwa Chen, Yves Van de Peer, Zhong-Jian Liu*. The genome sequence of the orchid Phalaenopsis equestris.Nature Genetics 2015 Jan; 47(1): 65-72. Epub 2014 Nov 24. [Nature Genetics Cover Article, featured in its Press Release and Research Highlights, News & Views; and worldwide attention and coverage]

[2] Wang ZY, Wu YP, Wang HF, Zhang YQ, Mei L, Fang XX, Zhang XD, Zhang F, Chen HB, Liu Y, Jiang YY, Sun SN, Zheng Y, Li N, Huang LQ*. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci USA (PNAS) 2014 Jan 7; 111(1): E89-98. Epub 2013 Dec 23.[Science Signaling Editors’ Choice, widely covered in the world; confirmed by European groups’ work that’s published 3 months later in Nature Cell Biology and highlighted by Nature Rev Mol Cell Biol and Nature Rev Cancer]

[3] Cao W, Liu Y, Huang LQ* et al. 2015. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells. Sci Rep 2015 (in press).

[4] Wu S, Ge YL, Huang LQ, Liu HY, Xue Y, Zhao Y. BRG1, the ATPase subunit of SWI/SNF chromatin remodeling complex, interacts with HDAC2 to modulate telomerase expression in human cancer cells. Cell Cycle 2014 Sep 15; 13(18): 2869-78.

[5] Liu Y, Cao W, Zhang B, Liu YQ, Wang ZY, Wu YP, Yu XJ, Zhang XD, Ming PH, Zhou GB, Huang LQ*.The natural compound magnolol inhibits invasion and exhibits potential in human breast cancer therapy. Sci Rep 2013 Nov 14;3: 3098.

[6] Zhang XD, Yang Y, Liang X, Zeng XW, Liu ZG, Tao W, Xiao XJ, Chen HB, Huang LQ*, Mei L. Enhancing therapeutic effects of docetaxel-loaded dendritic copolymer nanoparticles by co-treatment with autophagy inhibitor on breast cancer. Theranostics 2014 Aug 15; 4(11): 1085-95. eCollection 2014.

[7] O'Donnell AF, Huang LQ-arrestin Aly1/Art6.J Biol Chem 2013 Aug 16; 288(33): 24063-80. Epub 2013 Jul 3.a, Thorner J, Cyert MS.A calcineurin-dependent switch controls the trafficking function of

[8] Zhang XD, Zeng XW, Liang X, Yang Y, Li XM, Chen HB, Huang LQ, Mei L, Feng SS. The chemotherapeutic potential of PEG-b-PLGA copolymer micelles that combine chloroquine as autophagy inhibitor and docetaxel as an anti-cancer drug. Biomaterials 2014 Nov; 35(33): 9144-54. Epub 2014 Aug 7.

[9] Zhu YQ, Zheng Y, Mei L, Liu MQ, Li SS, Xiao HW, Zhu HJ, Wu S, Chen HB, Huang LQ*.Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus. Int J Oncol 2013 Oct; 43(4): 1151-59. Epub 2013 Jul 22.

[10] Wang ZY, Wu YP, Zeng XW, Ma YP, Liu J, Tang XL, Gao YF, Liu KW, Zhang JX, Ming PH, Huang LQ*,-caprolactone-ran-lactide) Nanoparticle-Based Delivery of Docetaxel in Mice Bearing Cervical Cancer. J Biomed Nanotechnol 2014 Aug; 10(8): 1509-19. Epub 2013.e-Tocopheryl Polyethylene Glycol 1000 Succinate-b-Poly (aMei L. Antitumor Efficiency of D-

[11] Zeng XW, Tao W, Wang ZY, Zhang XD, Zhu HJ, Wu YP, Gao YF, Liu KW, Jiang YY, Huang LQ, Mei L, Feng SS. Docetaxel-loaded nanoparticles of dendritic amphiphilic block copolymer H40-PLA-b-TPGS for cancer treatment. Part Part Syst Char 2015; 32(1): 112-22. Epub 2014 Jul 24.

[12] Tao W, Xiaowei ZengXW, Zhang JX, Zhu HJ, Chang DF, Zhang XD, Gao YF, Tang J, Huang LQ*, Mei L. Synthesis of cholic acid-core poly(ε-caprolactoneran-lactide)-b-poly (ethylene glycol) 1000 random copolymer as a chemotherapeutic nanocarrier for liver cancer treatment. Biomater Sci-UK 2014; 2(9): 1262–74. Epub 2014 Jun 18.